Restrictive Drug Coverage Policies can Induce Substantial Drug Exposure Misclassification in Pharmacoepidemiologic Studies

Clinical Therapeutics

Volumn 34, Issue 6, 2012, Pages

  Gamble, John Michael ^a   McAlister, Finlay A ^a,b   Johnson, Jeffrey A ^a   Eurich, Dean T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; RESPIRATORY TRACT AGENT;

AGE; ARTICLE; CANADA; DRUG EXPOSURE; DRUG LEGISLATION; DRUG MARKETING; HUMAN; INSURANCE; OBSERVATIONAL STUDY; PHARMACOEPIDEMIOLOGY; SOCIAL STATUS;

EID: 84862127955     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.04.009     Document Type: Article

References (31)

1. Weiss N.S. The new world of data linkages in clinical epidemiology: are we being brave or foolhardy?. Epidemiology 2011, 22:292-294.
2. Levy A., O'Brien B., Sellors C., et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003, 10:67-71.
3. Tamblyn R., Lavoie G., Petrella L., Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. J Clin Epidemiol 1995, 48:999-1009.
4. West S.L., Savitz D.A., Koch G., et al. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995, 142:1103-1112.
5. West S., Strom B., Freundlich B., et al. Completeness of prescription recording in outpatient medical records from a health maintenance organization. J Clin Epidemiol 1994, 47:165-171.
6. Tobi H., van den Heuvel N.J., de Jong-van den Berg L.T. Does uncollected medication reduce the validity of pharmacy dispensing data?. Pharmacoepidemiol Drug Saf 2004, 13:497-500.
7. Shrank W.H., Choudhry N.K., Fischer M.A., et al. The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med 2010, 153:633-640.
8. Jacobus S., Schneeweiss S., Chan K.A. Exposure misclassification as a result of free sample drug utilization in automated claims databases and its effect on a pharmacoepidemiology study of selective COX-2 inhibitors. Pharmacoepidemiol Drug Saf 2004, 13:695-702.
9. Yood M., Campbell U., Rothman K., et al. Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf 2007, 16:961-968.
10. Dreyer N.A. Making observational studies count: shaping the future of comparative effectiveness research. Epidemiology 2011, 22:295-297.
11. Schneeweiss S., Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005, 58:323-337.
12. Gamble J., McAlister F., Johnson J., Eurich D. Quantifying the impact of drug exposure misclassification due to restrictive drug coverage in administrative databases: a simulation study. Value Health 2012, 15:191-197.
13. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005, 353:487-497.
14. Antipsychotic Use in Seniors. Analysis in Brief Canadian Institute for Health Information, Accessed September 15, 2009. http://www.cihi.ca.
15. Bisphosphonates in Osteoporosis. Analysis in Brief Canadian Institute for Health Information, Accessed September 15, 2009. http://www.cihi.ca.
16. Drug Claims by Seniors: An Analysis Focusing on Potentially Inappropriate Medication Use, 2000-2006 Canadian Institute for Health Information, Accessed September 15, 2009. http://www.cihi.ca.
17. Hormone Replacement Therapy: An Analysis Focusing on Drug Claims by Female Seniors, 2000-2007. Analysis in Brief Canadian Institute for Health Information, Accessed September 15, 2009. http://www.cihi.ca.
18. Downey W., Stang M., Beck P., et al. Health services databases in Saskatchewan. Pharmacoepidemiology 2005, 295-310. John Wiley & Sons, Chichester, UK. 4th ed. B. Strom (Ed.).
19. Kozyrskyj A.L., Mustard C.A. Validation of an electronic, population-based prescription database. Ann Pharmacother 1998, 32:1152-1157.
20. Majumdar S.R., Almasi E.A., Stafford R.S. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 2004, 292:1983-1988.
21. Jackevicius C.A., Tu J.V., Ross J.S., et al. Use of fibrates in the United States and Canada. JAMA 2011, 305:1217-1224.
22. Patten S., Williams J., Metz L. Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis. Mult Scler 2008, 14:406-411.
23. Jackevicius C.A., Tu J.V., Ross J.S., et al. Use of ezetimibe in the United States and Canada. N Engl J Med 2008, 358:1819-1828.
24. Law M., Majumdar S., Soumerai S. Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study. BMJ 2008, 337:a1055.
25. Hanley J.A., Negassa A., Edwardes M.D., Forrester J.E. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 2003, 157:364-375.
26. Paterson J., Suleiman A., Hux J., Bell C. How complete are drug history profiles that are based on public drug benefit claims?. Can J Pharmacol 2008, 15:e108-e116.
27. Dormuth C., Carney G., Carleton B., et al. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009, 169:1395-1402.
28. Hamel M.B., Epstein A.M. Prior-authorization programs for controlling drug spending. N Engl J Med 2004, 351:2156-2158.
29. LeLorier J., Bell A., Bougher D., et al. Drug reimbursement policies in Canada-need for improved access to critical therapies. Ann Pharmacother 2008, 42:869-873.
30. Paris V., Docteur E. Pharmaceutical Policies and Reimbursement Policies in Canada. Health Working Papers, No 24 February 15, 2007, DELSA/HEA/WD/HWP(2006)4, Organization for Economic Co-operation and Development, Paris, France, Accessed January 4, 2012. http://www.oecd.org/dataoecd/21/40/37868186.pdf.
31. Valuck R., Jackson B. Secondary data analysis: commercial data. Research Methods for Pharmaceutical Practice and Policy 2011, 227-243. Pharmaceutical Press, London, UK. R.R. Aparasu (Ed.).